ZNTL Zentalis Pharmaceuticals Forecast, Technical & Fundamental Analysis
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC)... Show more
ZNTL is expected to report earnings to fall 4.00% to -47 cents per share on August 12
Q2'26
Est.
$-0.48
Q1'26
Est.
$-0.50
Q4'25
Missed
by $0.02
Q3'25
Beat
by $0.16
Q2'25
Beat
by $0.17
The last earnings report on May 12 showed earnings per share of -50 cents, meeting the estimate of -50 cents. With 302.44K shares outstanding, the current market capitalization sits at 261.97M.
A.I. Advisor
published General Information
General Information
a clinical-stage biopharmaceutical company, which focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer
A.I.dvisor indicates that over the last year, ZNTL has been loosely correlated with VCYT. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ZNTL jumps, then VCYT could also see price increases.
ZNTL in upward trend: price expected to rise as it breaks its lower Bollinger Band on May 18, 2026
ZNTL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 31 cases where ZNTL's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 67 cases where ZNTL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on June 22, 2026. You may want to consider a long position or call options on ZNTL as a result. In of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ZNTL advanced for three days, in of 272 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
ZNTL moved below its 50-day moving average on June 03, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ZNTL crossed bearishly below the 50-day moving average on June 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZNTL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for ZNTL entered a downward trend on June 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.434) is normal, around the industry mean (20.966). P/E Ratio (0.000) is within average values for comparable stocks, (36.007). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). ZNTL has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (6.812) is also within normal values, averaging (367.026).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ZNTL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZNTL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
